Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2602 • ACR Convergence 2024
Genetics of Sex Dimorphism in Clinical Manifestations of Systemic Lupus Erythematosus
Caseng Zhang¹, Nicholas Gold², Raffaella Carlomagno³, JingJing Cao⁴, Daniela Dominguez⁴, Dafna Gladman⁵, Mariko Ishimori⁶, Caroline Jefferies⁷, Diane Kamen⁸, Sylvia Kamphuis⁹, Marisa Klein-Gitelman¹⁰, Andrea Knight¹¹, Chia-Chi Lee¹², Deborah Levy², Lawrence Ng², Karen Onel¹³, Andrew Paterson⁴, Christine Peschken¹⁴, Janet Pope¹⁵, Earl Silverman¹⁶, Zahi Touma¹⁷, Murray Urowitz¹⁸, Daniel Wallace¹⁹, Joan Wither²⁰ and Linda Hiraki², ¹University of Ottawa, Ottawa, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Lausanne University Hospital, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Cedars-Sinai Health System, Los Angeles, CA, ⁷Cedars-Sinai Medical Center, Beverly Hills, CA, ⁸Medical University of South Carolina, Charleston, SC, ⁹Erasmus University Medical Center, Rotterdam, Netherlands, ¹⁰Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ¹¹Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹²Cedars-Sinai Medical Center, Los Angeles, CA, ¹³HSS, New York, NY, ¹⁴University of Manitoba, Winnipeg, MB, Canada, ¹⁵University of Western Ontario, London, ON, Canada, ¹⁶Silverman, Toronto, ON, Canada, ¹⁷University of Toronto, Toronto, ON, Canada, ¹⁸Self employed, Toronto, ON, Canada, ¹⁹Cedars Sinai Medical Center, Studio City, CA, ²⁰University Health Network, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease with multi-organ involvement and a strong female predominance. Prior studies demonstrated sex dimorphism in…
Abstract Number: 2682 • ACR Convergence 2024
The Forgotten Costs of SLE: Estimating Indirect Costs in a National SLE Cohort
Ann E. Clarke¹, Yvan St-Pierre², Megan Barber¹, Sasha Bernatsky³, Evelyne Vinet⁴, Christian Pineau⁵, Murray Urowitz⁶, Dafna Gladman⁷, Christine Peschken⁸, John Hanly⁹, Alexandra Legge¹⁰ and Paul Fortin¹¹, ¹Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²McGill University Health Center, Montreal, QC, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Centre, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Self employed, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ¹⁰Dalhousie University, Halifax, NS, Canada, ¹¹Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Economic analyses of SLE often include only direct healthcare costs. Indirect costs, particularly those attributable to lost productivity in unpaid labour, are often overlooked,…
Abstract Number: L02 • ACR Convergence 2023
Mutational Analysis of UNC93B1 Identifies Regulatory Regions Mutated in Human SLE
John Huizar¹, Victoria Rael², Julian Yano², Leianna Slayden³, Madeleine Weiss⁴, Robert Saxton⁴, Bo Liu⁵, Olivia Majer⁶ and Gregory Barton⁷, ¹UCSF, San Francisco, CA, ²Division of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, UC Berkeley, Berkeley, CA, ³HHMI at UC Berkeley, Berkeley, CA, ⁴UC Berkeley, Berkeley, CA, ⁵Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shangai, China, ⁶Max Planck Institute for Infection Biology, Berlin, Germany, ⁷UC Berkeley / HHMI, Berkeley, CA
Background/Purpose: Endosomal nucleic acid-sensing toll-like receptors 3, 7 and 9 are key innate immune sensors of dsRNA, ssRNA and ssDNA, respectively, whose activities must be…
Abstract Number: L13 • ACR Convergence 2023
An Open-label, Multicenter, Phase 1/2 Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323, a Rapid Manufacturing CAR-T Cell Therapy Targeting CD19 on B Cells, for Severe Refractory Systemic Lupus Erythematosus: Preliminary Results
Josefina Cortés Hernández¹, Pere Barba², Mònica Linares Alberich³, Ozana Fischer⁴, Beata Kovacs⁴, Thomas Calzascia⁴, David Pearson⁴, Ana-Laura Jordán Garrote⁵, Tiina Kirsilä⁴, Richard Siegel⁴, Tamas Shisha⁴, Giulio Cavalli⁴ and Peter Gergely⁴, ¹Vall d'Hebron Institute of Research (VHIR) and Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain, ²Vall d'Hebron Institute of Oncology and Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain, ³Banc de Sang i Teixits, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain, ⁴Novartis Biomedical Research, Basel, Basel-Stadt, Switzerland, ⁵Novartis Farmacéutica, Barcelona, Catalonia, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by pathogenic autoreactive B cells producing autoantibodies against multiple self-antigens. Recently, a series of clinical cases suggested that…
Abstract Number: L17 • ACR Convergence 2023
Safety, Tolerability, and Exploratory Efficacy of Afimetoran, a TLR7/8 Inhibitor, in Patients with Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study
Fareeda Hosein¹, Stanislav Ignatenko², Kristina Chadwick¹, Lin Zhu¹, Frédéric Baribaud¹, Thanh Bach¹, Hazem Karabeber¹, Michelle Dawes¹, Leon Carayannopoulos¹ and Gopal Krishna¹, ¹Bristol Myers Squibb, Princeton, NJ, ²Charité Research Organisation GmbH, Berlin, Germany
Background/Purpose: Over 50 years have passed since the last therapy was approved for cutaneous lupus erythematosus (CLE).1 Parenteral administration, off-label use, or toxicity with long-term…
Abstract Number: 0067 • ACR Convergence 2023
Dimethyl Fumarate Modulates T Cell Metabolism and Function in Systemic Lupus Erythematosus Patient Samples
Loren Kell¹, Samuel Taylor², Kavina Shah², Roel De Maeyer², Debajit Sen², Madhura Castelino², Jo Cambridge², David Isenberg², Maria Leandro³, Arne Akbar² and venkat Reddy², ¹University College London, Oxford, United Kingdom, ²University College London, London, United Kingdom, ³University College London/UCLH, London, United Kingdom
Background/Purpose: Activated T cells make a significant contribution to inflammation in systemic lupus erythematosus (SLE). We know that cellular metabolism regulates the activation of T…
Abstract Number: 0178 • ACR Convergence 2023
Traditional and Lupus-Specific Risk Factors for Cardiovascular Events Among Patients with Systemic Lupus Erythematosus
Saloni Patolia, Dulaney Wilson, Jim Oates and Diane L. Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Even among young women with systemic lupus erythematosus (SLE), accelerated atherosclerosis and coronary artery disease are common complications. Traditional risk scoring methods underestimate cardiovascular…
Abstract Number: 0325 • ACR Convergence 2023
Understanding the Burden of Cutaneous Lupus: A Subset Analysis from the 2022 World Lupus Federation Global Impact (WLFGI) Patient Survey
Nnenna Ezeh¹, Joy Buie², Mike Donnelly³, Daria McClamb³, Lydia Oberholtzer⁴, Jana Sharp⁴ and Joseph Merola⁵, ¹Department of Dermatology; Department of Medicine, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ²Lupus Foundation of America, York, SC, ³Lupus Foundation of America, Washington, DC, ⁴Sharp Insight, LLC, Montgomery County, MD, ⁵Harvard Medical School, Brigham and Women's Hospital, Newton, MA
Background/Purpose: There is a paucity of data among a global population exploring the burden of CLE on patients, especially as compared to patients with SLE.…
Abstract Number: 0551 • ACR Convergence 2023
Monogenic Lupus: Clinical Phenotypes and Genetic Mutations in a Cohort of Pediatric Patients
Keerthi Vardhan Yerram¹, Kavitha Shanigaaram¹, Gaurang Sudhir Deshpande¹, Akshay Parikh¹, Arjun Ramavath¹, Nanditha Gollakota¹, Ramesh Manthri¹ and Liza Rajasekhar², ¹Department of Clinical Immunology and Rheumatology, Nizams Institute of Medical Sciences, Hyderabad, India, ²Nizam's Institute of Medical Sciences, Madhapur, India
Background/Purpose: Monogenic lupus is associated with specific gene mutations, most commonly reported in TREX1, DNASE1L3, DNASE2, and SAMHD1. However, their phenotypes are not well reported.…
Abstract Number: 0568 • ACR Convergence 2023
Comparison of Plasma Protein Profiles and Endothelial Function in Patients with Pediatric-Onset Systemic Lupus Erythematosus and Healthy Controls
Liyoung Kim¹, Gabrielle Alonzi¹, Marina Barguil Macedo², Pamela F. Weiss³, Jane Newburger⁴, Karen Costenbader⁵, Christian Lood² and Joyce Chang¹, ¹Boston Children's Hospital, Boston, MA, ²University of Washington, Seattle, WA, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Boston Children's Hospital, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Patients with pediatric-onset systemic lupus erythematosus (pSLE) have elevated cardiovascular (CV) risk associated with accelerated atherosclerosis that begins in childhood. Endothelial dysfunction may be…
Abstract Number: 0586 • ACR Convergence 2023
Therapeutic Drug Monitoring of Azathioprine and Tacrolimus in SLE Pregnancies: Preliminary Results from the LEGACY Cohort
Reem Farhat¹, Arielle Mendel², Isabelle Malhamé³, Joo Young (Esther) Lee⁴, Luisa Ciofani⁵, Sasha Bernatsky⁶ and Evelyne Vinet², ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵McGill University Health Center, Montreal, QC, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Pregnant SLE women still face an unacceptably high risk of maternal and fetal morbidity, particularly when their disease is active. How to personalize SLE…
Abstract Number: 0604 • ACR Convergence 2023
Is Belimumab Dose Optimization Possible in Patients with Systemic Lupus Erythematosus?: Analysis of This Therapeutic Strategy in a Large Multicenter Cohort of Patients from Spanish Rheumatology Departments
Irene Altabas Gonzalez¹, Jose-Maria Pego-Reigosa², CORAL Mourino Rodriguez³, Norman Jiménez⁴, Andrea Hernández-Martín⁵, Judit Font⁶, Ivette Casafont-Sole⁷, Jose Andres Roman Ivorra⁸, Marta De la Rubia Navarro⁹, Maria Galindo¹⁰, TAREK CARLOS SALMAN MONTE¹¹, Javier Narvaez¹², Paola Vidal-Montal¹³, Maria J. García-Villanueva¹⁴, Sandra Garrote Corral¹⁴, María Ángeles Blázquez Cañamero¹⁵, carlos Marras Fernández-Cid¹⁶, María Piqueras García¹⁷, JULIA MARTINEZ BARRIO¹⁸, Marina Sánchez-Lucas¹⁹, Josefina Cortés Hernández²⁰, Eleonora Penzo²¹, Jaime Calvo Alén²², Juan Ramón de Dios Jiménez de Aberásturi²³, Belén Álvarez Rodríguez²⁴, Margarida Rocha²⁵, Eva Tomero Muriel²⁶, Raúl Menor-Almagro²⁷, Myriam Gandía Martínez²⁸, Jose A Gomez-Puerta²⁹, Beatriz Frade³⁰, Consuelo Ramos-Giráldez³¹, Carmen Trapero Pérez³², MARIA ELVIRA DIEZ ALVAREZ³³, Clara Moriano Morales³³, Alejandro Muñoz³⁴ and Iñigo Rúa-Figueroa³⁵, ¹Complejo Hospitalario Universitario de Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ²Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ³Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ⁴IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ⁵Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain, ⁶Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁸Hospital Universitari i Politècnic la Fe, Valencia, Spain, ⁹Hospital Universitario y Politécnico de la Fe, Valencia, Spain, ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹²Hospital Universitario de Bellvitge, Barcelona, Spain, ¹³Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁴Hospital Ramón y Cajal, Madrid, Spain, ¹⁵Rheumatology Department Hospital Ramon y Cajal, Madrid, Spain, ¹⁶Rheumatology, Hospital Virgen Arrixaca, Murcia, Spain, ¹⁷Hospital Virgen de la Arrixaca de Murcia, Murcia, Spain, ¹⁸Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ¹⁹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²⁰Lupus Unit, Rheumatology Department, Vall d’Hebron Hospitals, Barcelona, Spain, ²¹Hospital Universitario Valle d´ Hebrón, Barcelona, Spain, ²²Hospital Universitario Araba, Vitoria, Spain, ²³Hospital Universitario Araba, Álava, Spain, ²⁴Hospital de Araba, Vitoria, Spain, ²⁵Osakidetza, Bilbo, Spain, ²⁶Rheumatology, Hospital La Princesa, Madrid, Spain, ²⁷Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ²⁸Hospital de Jerez, Jerez, Spain, ²⁹Department of Rheumatology, Hospital Clinic of Barcelona, Barcelona, Spain, ³⁰Hospital Clinic, Barcelona, Spain, ³¹Rheumatology Department Hospital Universitario Virgen de Valme, Sevilla, Spain, ³²Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain, ³³Rheumatology, Hospital Universitario de León, León, Spain, ³⁴Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ³⁵Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain
Background/Purpose: Belimumab (BLM) is an IgG-1l anti-BAFF monoclonal antibody effective in patients with systemic lupus erythematosus (SLE), being used increasingly. However, there are no published…
Abstract Number: 0826 • ACR Convergence 2023
Development of a Decision Aid for Clinical Trial Participation in Systemic Lupus Erythematosus
Leila Khalili¹, Rita Kukafka², Laura Geraldino-Pardilla¹, Nancyanne Schmidt¹, Sean Inzerillo¹, Julia Weiner¹, Wei Tang¹ and Anca Askanase³, ¹Division of Rheumatology, Columbia University Irving Medical Center, New York, NY, ²Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, ³Columbia University Medical Center, New York, NY
Background/Purpose: Standard of care therapy for SLE relies heavily on broad-spectrum immune suppressants. Therapeutic drug development is critical to the approval of targeted therapies; however,…
Abstract Number: 0897 • ACR Convergence 2023
Steroid-sparing Effects of Afimetoran (BMS-986256), an Equipotent Toll-like Receptor (TLR)7 and TLR8 Antagonist, in a Lupus Mouse Model
Shailesh Dudhgaonkar¹, Puneet Chopra², Anjuman Rudra², Siva Subramani², Sourabha Palachandra², Nikita Bhatt², Veeresh Pabbala², Sourabh Ranade², Durga Siva Prasad Ega², Alaric Dyckman³ and Qihong Zhao³, ¹Bristol Myers Squibb, Bangalore, India, ²Biocon Bristol Myers Squibb Research Center, Bangalore, India, ³Bristol Myers Squibb, Lawrenceville, NJ
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with extensive phenotypic heterogeneity due to the underlying molecular diversity of dysregulated pathways. Patients with…
Abstract Number: 0916 • ACR Convergence 2023
Upregulation of the M-CSF Receptor on Non-Classical Monocytes from SLE Patients as an Indicator for Premature Monocyte Aging
Markus Zeisbrich¹, Stephanie Finzel², Nils Venhoff¹ and Reinhard Voll¹, ¹University Medical Center Freiburg, Freiburg, Germany, ²Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany
Background/Purpose: Circulating monocytes are divided into three subsets: classical, intermediate, and non-classical monocytes. Monocytes egress from the bone marrow as classical monocytes and develop into…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].